Postoperative serum CA19-9, YKL-40, CRP and IL-6 in combination with CEA as prognostic markers for recurrence and survival in colorectal cancer by Hermunen, Kethe et al.
 1 
Post-operative serum CA19-9, YKL-40, CRP, and IL-6 in combination with CEA 
as prognostic markers for recurrence and survival in colorectal cancer.   
Kethe Hermunen1, Leena-Maija Soveri2,3, Mogens Karsbøl Boisen4, Harri K. Mustonen1,5, Christian 
Dehlendorff6, Caj H. Haglund1,5*, Julia Sidenius Johansen4,7,8*, and Pia Osterlund2,9* 
1 Department of Gastrointestinal Surgery, University of Helsinki and Helsinki University Hospital, 
PO BOX 4, 00014 University of Helsinki, Finland  
2 Department of Oncology, University of Helsinki and Helsinki University Hospital, BO BOX 180, 
00029 HUS (Helsinki), Finland  
3 Hyvinkää Hospital and Hyvinkää Homecare, Hyvinkää, Sairaalankatu 1, 05850 Hyvinkää, Finland.  
4 Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, 
Borgmester Ib Juuls vej 1, DK-2730 Herlev, Denmark 
5 Research Programs Unit, Translational Cancer Medicine Program, University of Helsinki, PO Box 
4, 00014 Helsinki, Finland 
6 Statistics and Pharmacoepidemiology, Danish Cancer Society Research Center, Danish Cancer 
Society, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.  
7 Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, 
Borgmester Ib Juuls vej 1, DK-2730 Herlev, Denmark 
8 Institute of Clinical Medicine, Faculty of Health and Medical Sciences, University of 
Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen N, Denmark 
9 Department of Oncology, University of Tampere and Tampere University Hospital. Teiskontie 35, 
33621 Tampere, Finland. 
* equal last authorship 
Short heading: CA19-9, YKL-40, CRP and IL-6 in addition to CEA 
Keywords: CA19-9, CEA, CRP, colorectal cancer, IL-6, YKL-40 
Word count: 3292, 3 Tables and 2 Figures  
 2 
ABSTRACT        
Background: 
In colorectal cancer (CRC) patients, guidelines only recommend measurement of pre-operative 
carcinoembryonic antigen (CEA), although post-operative CEA may be more informative. 
However, the sensitivity of both pre-operative and post-operative CEA in identifying relapse is 
limited. We studied whether CA19-9, YKL-40, C-reactive protein (CRP), and interleukin (IL)-6 
add prognostic information combined with post-operative CEA. 
Material and methods: 
This post-hoc analysis included 147 radically resected stage II (n=38), III (n=91), and IV (n=18) 
CRC patients treated with adjuvant 5-fluorouracil (5-FU)-based therapy in the phase III LIPSYT 
study (ISRCTN98405441). We collected post-operative blood samples a median 48 days after 
surgery. We analysed relapses, sensitivity, positive predictive value (PPV), and disease-free (DFS) 
and overall survival (OS) by bootstrap, Kaplan-Meier, and adjusted Cox-models in the elevated vs. 
normal biomarker groups.  
Results: 
Elevated post-operative CEA associated with impaired DFS (HR 7.23; CI95% 3.85-13.58), impaired 
OS (HR 7.16; CI95% 3.76-13.63), and more relapses (HR 7.9; CI95% 3.4-18.2); but sensitivity for 
CEA in finding relapses was only 31% (CI95% 21-48%). Normal CEA combined with an elevated 
YKL-40 or elevated CRP showed more relapses (HR for YKL-40 2.13 [CI95% 1.10-4.13],  HR for 
CRP 3.14; [CI95% 1.21-8.16]), impaired DFS (HR 2.18 [CI95% 1.12-4.24] or 3.23 [CI95% 1.34-7.82]), 
and impaired OS (2.33 [CI95%1.24-4.40] or 2.68 [CI95%1.12-6.44]). Elevated CEA combined with a 
concomitantly elevated CA19-9, YKL-40, CRP, or IL-6 showed a respective PPV of 100%, 90%, 
100%, and 100%.  
Conclusion: 
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In radically operated stage II to IV CRC patients who received adjuvant 5-FU-based, a post-
operatively elevated CEA alone or in combination with CA19-9, YKL-40, CRP, or IL-6, or a 
normal CEA combined with an elevated YKL-40 or with an elevated CRP, may indicate patients at 




Treatment of choice for locoregional colorectal cancer (CRC) and resectable metastases is surgery 
with curative intent. Despite improvements achieved in surgery and in adjuvant chemotherapy, 30-
50% of stage II-III patients and 50% with resected stage IV disease will develop a recurrence [1-4].  
There is a need for biomarkers to determine patients´ risk for recurrence; routine high-risk factors 
have proven unsatisfactory [1, 3, 4]. Several new multigene assays provide individualized 
prognostic information, and liquid biopsies are emerging as a method to detect minimal residual 
disease. Yet, methodologically, these are challenging technologies, and data to support their use in 
everyday clinical practice are insufficient [3-5]. 
Blood-based biomarkers are easy to sample and could be ideal for evaluating risk of cancer 
recurrence. CEA, carcinoembryonic antigen, is a tumour-associated glycoprotein, rather than a 
tumour-specific marker. For years, CEA has been the only widely recommended biomarker for 
CRC prognostics and follow-up [6, 7]. However, the sensitivity of pre-operative CEA in detecting 
CRC recurrence is only 50–80%, and the specificity 80% [8]. There are studies showing that, post-
operative CEA is more informative than pre-operative CEA [9, 10]. New biomarkers are therefore 
essential to improve CEA’s clinical utility.   
CA19-9, carbohydrate antigen 19-9, is a widely used marker in gastrointestinal cancers [11], but its 
prognostic value after resection of CRC is less established [6, 7]. CRC is associated with 
inflammation, which promotes carcinogenesis and tumour growth [12]. Therefore, inflammation-
related biomarkers or mediators such as YKL-40 (also known as human cartilage glycoprotein-39 
or chitinase-3-like-1 protein), c-reactive protein (CRP), and interleukin (IL)-6 have emerged as 
prognostic biomarkers. YKL-40 is a secreted protein produced by non-malignant cells such as 
macrophages and by cancer cells such as colon cancer cells [13]. YKL-40 promotes cancer 
proliferation and inflammatory cytokine production [14]. CRP is a non-specific acute-phase 
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reactant reflecting  tissue damage, and  is also a sensitive and stable marker of inflammation [15]. In 
cancer patients, including CRC, elevated serum CRP is associated with inflammation, cachexia, and 
poor prognosis both in metastatic and localized disease [16]. IL-6,  mainly produced by monocytes 
and macrophages, among others, as well as by various tumour cells [17] stimulates YKL-40 
production and angiogenesis; it  is regarded as an important tumour-promoting factor in various 
human cancers, including CRC [18]. Our aim was to evaluate the prognostic value of post-operative 
CA19-9, YKL-40, CRP, and IL-6 in combination with CEA in radically resected stage II-IV CRC 




MATERIAL AND METHODS 
The original LIPSYT trial was an open-label, prospective, randomised single-institution study in 
patients with radically resected CRC (http://www.controlled-    
trials.com/ISRCTN98405441). Patients included received treatment at the Department of Oncology 
of Helsinki University Hospital Finland) between November 1997 and August 2001. That study’s 
primary aim was to assess treatment tolerability in a two-by-two factorial design; the secondary aim 
was to study biomarkers.  
This is a post hoc analysis of the LIPSYT trial, with 150 patients, of which 3 never started 
treatment. Inclusion criteria were age 18 to 75 years, histologically confirmed radically resected 
stage II–IV CRC (radical metastasectomy of mostly liver metastases, n=18), WHO performance 
status 0–2 and adequate bone-marrow-, kidney-, and liver function. Exclusion criteria included 
history of invasive cancer other than CRC; metabolic, neurological, or psychiatric illness 
incompatible with chemotherapy; serious thromboembolic event currently under treatment; 
pregnancy, lactation, or absence of adequate contraception in fertile patients. The protocol was 
approved by an institutional review board and all study participants gave their signed informed 
consent. Adjuvant chemotherapy consisted of 5-FU and LV as bolus injection (Mayo regimen) or 
continuous infusion (simplified de Gramont regimen) according to randomization [19]. 
Assessment of biomarkers 
CEA, YKL-40, CRP, IL-6, and CA19-9 were measured in serum samples collected post-operatively 
before adjuvant chemotherapy began. Median time from surgery to laboratory sampling and 
treatment initiation was 48 days (range 19-124) and more than 8 weeks in 40 (27%). The reason for 
treatment delay was referral-delay to oncology for 33 patients, and 7 patients being unfit to start 
oncologic treatments within 8 weeks. 
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CRP, CEA, and CA19-9 were determined by the routine laboratory of the university hospital with 
automatic analyzers as follows: CRP: immunoturbidimetric method, CEA and CA19-9: 
immunoenzymatic assay, Bayer Immuno 1 (CEA: 10/1998-10/2005; and CA19-9: 1/1998-1/2006), 
or immunochemiluminometric assay, Abbott Architect (CEA: 10/2005→ and CA19-9: 1/2006→). 
All measurements were performed by technicians blinded to study endpoints. 
Blood samples for YKL-40 and IL-6 were collected in gel tubes and centrifuged within 2 hours; 
serum was stored at -20 C until analysis. YKL-40 and IL-6 were determined in duplicate with    
commercially available enzyme-linked immunosorbent assays (ELISAs); YKL-40: MicroVue 
YKL-40 ELISA (Catalog #8020), Quidel Corporation, San Diego, CA, USA; and IL-6: Quantikine 
HS600B, R&D Systems, Abingdon, OX, UK; according to manufacturer’s instructions. For YKL-
40, the detection limit was 20 ng/ml and intra- and inter-assay coefficients of variation (CVs) of 
<5% and <6% [17]. For IL-6, detection limit was .01 pg/ml and intra- and inter-assay CVs of ≤8% 
and ≤11% [20].  
An age-corrected percentile for YKL-40 was calculated according to the formula [17]: 
percentile=100 / (1+ (YKL-40 ^−3) * (1.062 ^ age) * 5000).  Cut-off values were: ROC corrected 
cut-off for age-corrected YKL-40 level as the 70.7th percentile of normal controls YKL-40 (see 
statistics), 4.5 pg/ml for IL-6 [20]; 10 mg/l for CRP; 5 µg/l for CEA; and 26 kU/l for CA19-9 
according to clinical routine at HUSLab, Helsinki, Finland.  
 
Statistics 
Clinicopathological parameters and tumour-marker values are presented as frequencies or medians 
with range for nonparametric distributions. The chi-squared test served for comparisons between 
categorical variables, and the Mann-Whitney or Kruskall-Wallis for non-normally distributed 
continuous variables.  
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Time-dependent receiver-operating characteristic (ROC) curves were constructed for DFS at 5 
years of follow-up, and area under the curve (AUC) values determined (timeROC package in R, 
https://cran.r-project.org/web/packages/timeROC/v0.3 by Paul Blanche). The cut-off value for 
YKL-40 (70.7th) was obtained by maximizing Youden’s index at 5 years of follow-up, giving 
sensitivity and specificity equal weight.  
Descriptive survival analysis was performed with the Kaplan–Meier estimator, and the log-rank test 
served to compare groups. Disease-free survival (DFS) was defined as a composite endpoint of 
recurrence or death from any cause with censoring at the last date of follow-up at 10+ years from 
post-operative sampling. The endpoint for overall survival (OS) was death from any cause with 
censoring at the last date of follow-up. Median follow-up time for patients alive was 11.9 (range 
8.9-12.7) years. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CI95%) 
were estimated with the Cox regression proportional hazard model. Firth's penalized maximum 
likelihood bias correction method for Cox regression was used, if mentioned.  
Adjustment was for age, sex, inflammatory disease, and stage in univariate analysis and further for 
CEA, CA19-9, YKL-40, CRP, and IL-6 in multivariate models. Inflammatory disease was a history 
of autoimmune disease such as rheumatoid arthritis, iritis, psoriasis, ulcerative colitis, coeliac 
disease, and thyroiditis in 14 patients. None had active ulcerative colitis. For the multivariate 
model, all biomarkers with background variables were included (into the model). Relapse events at 
7 years were defined as CRC recurrence (distant or local), new CRC, or death from CRC, but new 
non-CRC cancer or deaths from other causes were not events. Specificity, sensitivity, and positive 
predictive value (PPV) for a biomarker being elevated vs. normal were calculated for relapse at 7 
years by using non-colorectal deaths as competing events. The 95% bias-corrected accelerated CIs 
(BCa) were obtained by a bootstrapping method with 1000 replications (boot package in R [21]). 
The Clopper-Pearson confidence interval was calculated for PPV in subgroup analysis. Relapse was 
analysed with the Cox proportional hazards regression, with other deaths as competing risks, and 
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adjusted for age (median cut off), sex, inflammatory disease, and TNM stage. Subgroup analyses 
are, however, unadjusted. 
The statistical significance level was set at 5%; all tests were two-sided. Statistical analyses were 
done with SPSS version 24.0 (IBM SPSS Statistics, version 22.0 for Mac; SPSS, Inc., Chicago, IL, 
USA), R version 3.6.1 (Foundation for Statistical Computing, Vienna, Austria), SAS for Windows 
(v9.4, SAS institute Inc., Cary, NC, USA) and STATA/MP (v.15.1, StataCorp LLC, College 





Baseline characteristics and biomarker levels 
The 147 patients were of median 60 years (range 31-76) and most presented with a locoregional 
disease (88% stage II-III, Table 1). After 10 years, 77 (52%) were still alive. Relapse was detectable 
in 65 (44%), with no new relapses after 6.3 years. Cause of death was metastatic CRC (mCRC) in 
84% (58/70), cardiovascular in 10% (7/70), second cancer in 3% (2/70), and other cause in 3% 
(2/70). Levels of CEA, CA19-9, YKL-40, or CRP, according to primary location (right colon vs. 
left colon vs. rectum), showed no differences, but in patients with rectal cancer (Table 1), IL-6 was 
higher.   
 
CEA 
Elevated CEA showed an increased hazard of relapse; the HR adjusted for background variables 
was 7.91 (CI95% 3.43-18.24, other deaths as competing risk; Table 2). For CEA elevated vs. normal, 
the specificity was 97% (CI95% 91-100), sensitivity 31% (CI95% 21-48), and PPV 89%, CI95% (65-
99%; Table 2). 
In univariate analysis adjusted for baseline characteristics, elevated CEA associated with impaired 
DFS (HR 7.23, CI95% 3.85-13.58; 10-year DFS rate 6% for elevated CEA vs. 63% for normal CEA; 
Table 3, Figure 1A) and impaired OS (HR 7.16, CI95% 3.76-13.63); 10-year OS rate 6% for elevated 
CEA vs. 68% for normal CEA; Table 3, Figure 1B).  
In multivariate analysis, elevated CEA associated with impaired DFS (HR 8.63, CI95% 3.82-19.50) 




Elevated CA19-9 levels vs. normal had an adjusted HR of 2.08 (95% CI .87-4.98) for relapse, using 
other deaths as competing events. Elevated vs. normal CA19-9 showed sensitivity of 16% (CI95% 8-
27%), specificity 89% (CI95% 79-95%), and PPV 53% (CI95% 27-78%, Table 2). No association 
appeared between elevated CA19-9 and DFS or OS (Table 3), which was true also for the subgroup 
with elevated CA19-9 and normal CEA.  
All five patients with concomitantly elevated CEA and CA19-9 relapsed (PPV 100%, CI95% 48-
100%, the Clopper–Pearson interval), had a numerically shorter DFS (.41 vs. .76 years, HR 3.16 
CI95% .82-14.0, with Firth’s bias correction) and significantly shorter OS (1.8 vs. 2.9 years, HR 
4.46; CI95% 1.1-20.0, Firth’s bias correction), compared to patients with either elevated or both 
normal.    
 
YKL-40 
Elevated YKL-40 showed an increased hazard of relapse; HR adjusted for background variables 
being 1.73 (CI95% 1.02-2.93, other deaths as competing risk). The sensitivity for finding relapses 
was 56% (CI95% 43-69), specificity 69% (CI95% 58-79), and PPV 57% (CI95% 45-69%; Table 2). In 
univariate analysis, elevated YKL-40 vs. normal associated with impaired DFS (HR 1.84, CI95% 
1.14-2.96, 10-year DFS rate 37% vs. 59%) and impaired OS (HR 1.97, CI95% 1.20-3.23, 10-year OS 
rate 43% vs. 64%; Table 3). In adjusted multivariate analysis, elevated YKL-40 associated with 
impaired OS (HR 2.24, CI95% 1.23-4.05), but not with impaired DFS (HR 1.58, CI95% .88-2.86; 
Table 3).   
In the subgroup with normal CEA, elevated YKL-40 had an unadjusted HR of 2.13 (95% CI 1.10-
4.13) for relapse, impaired DFS (HR 2.30, CI95% 1.27-4.16; Figure 2A), and OS (HR 2.40, CI95% 
1.28-4.52; Figure 2B) compared with normal YKL-40. Patients with normal CEA and elevated 
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YKL-40 had a 10-year DFS rate of 49% vs. 71% in patient with both normal, and a 10-year OS rate 
of 55% vs. 77%. 
In  the small subgroup with concomitant elevation of both YKL-40 and CEA, nine of ten patients 
without competing deaths had a relapse (PPV 90%, CI95% 56-100%, Clopper–Pearson interval; 
Table 2), numerically shorter DFS (.68 vs. .76 years, HR .82, CI95% .31-2.15) and numerically 




Elevated CRP levels vs. normal levels had an adjusted HR of 1.95 (CI95% .97-3.94) for relapse using 
other deaths as competing events. Elevated CRP showed sensitivity of 20% for finding relapses 
(CI95% 12-30%), specificity of 96% (CI95% 89-99%) and PPV of 77% (CI95% 44-93%; Table 2). In 
univariate analysis, elevated vs. normal CRP associated with impaired DFS (HR 2.31, CI95% 1.21-
4.39; 10-year DFS rate 18% vs. 53%) and impaired OS (HR 2.40, CI95% 1.20-4.80; 10-year OS rate 
24% vs. 59%). In adjusted multivariate analysis, elevated CRP associated with impaired DFS (HR 
2.53; CI95% 1.10-5.81), but not with OS (HR 2.49; CI95% .95-6.51; Table 3).   
In the subgroup with normal CEA and elevated CRP, unadjusted HR for relapse was 3.14 (CI95% 
1.21-8.16). Patients with normal CEA and elevated CRP had an impaired DFS (HR 3.54, CI95% 
1.57-8.02; Figure 2C) and an impaired OS (HR 3.10, CI95% 1.29-7.45; Figure 2D) compared with 
patients with normal CEA and normal CRP. Patients with normal CEA and elevated CRP had a 10-
year DFS rate of 30% vs. 65% with normal CEA and normal CRP, and a 10-year OS rate of 40% 
vs. 71%. 
All four patients with concomitant elevation of CEA and CRP had a relapse (PPV 100%, CI95% 40-
100%; Table 2), numerically shorter DFS (.39 vs. .76 years, HR 3.13, CI95% .90-10.90), and 
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numerically shorter OS (1.8 vs. 2.6 years, HR 1.52, CI95% .48-4.77) than did patients with either 
elevated or both normal. 
 
IL-6 
Elevated IL-6 predicted increased hazard of relapse; HR adjusted for background variables was 
2.12 (CI95% 1.11-4.03, other deaths as competing risk). Sensitivity for elevated IL-6 in finding 
relapses was 28% (CI95% 17-40%), specificity 91% (CI95% 84-97%) and PPV 75% (CI95% 53-90%; 
Table 2). In univariate analysis, elevated IL-6 associated with impaired OS (HR 1.99, CI95% 1.05-
3.76; 10-year OS rate for elevated IL-6 vs. normal IL-6 was 33% vs. 58%) but not with impaired 
DFS (HR 1.77, CI95% .95-3.30, 10-year DFS rate for elevated IL-6 vs. normal IL-6 being 25% vs. 
53%; Table 3). In multivariate analysis, IL-6 was not an independent biomarker of DFS or OS 
(Table 3).   
Normal CEA and elevated IL-6 did not associate with impaired DFS (HR 1.36, CI95% .53-3.51) or 
impaired OS (HR 1.30, CI95% .48-3.51).  
All six patients with concomitantly elevated CEA and IL-6 relapsed (PPV 100%, CI95% 54-100%) 
and, had a numerically shorter DFS (.41 vs. .76, HR 2.16, CI95% .75-6.16) and OS (1.1 vs. 2.6, HR 
1.96, CI95% .71-5.44) than did patients with either elevated or both normal.   
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DISCUSSION 
The present study demonstrates that post-operatively elevated serum CEA, YKL-40, CRP, and IL-6 
predict recurrence and impaired survival, but in adjusted multivariate analysis only CEA remained 
significantly associated with both impaired DFS and impaired OS. In patients with normal CEA and 
elevated YKL-40 or CRP, their DFS and OS were impaired. If elevated CEA was combined with 
elevated CA19-9, YKL-40, CRP, or IL-6, the risk of CRC relapse was very high (90-100%) and the 
OS short. If validated, these concomitantly elevated biomarkers may prove useful for identifying 
patients suitable for a more intensive follow-up to earlier identify resectable metastases, and in 
identifying low-risk patients who may need adjuvant chemotherapy or high-risk who need addition 
of oxaliplatin.   
According to guidelines, CEA is the only biomarker that should be routinely measured in patients 
with CRC [6, 7]. Elevated preoperative CEA has been shown to be an important prognostic factor 
in addition to TNM stage and other known prognostic factors [22, 23]. However, both the 
sensitivity and specificity of CEA are limited, and a notable part of high-risk patients can remain 
undetected if only CEA is measured [8, 24, 25]. In the Cochrane review, CEA was insufficiently 
sensitive, even with low thresholds (<2.5) and they concluded that a rise in CEA never occurs in up 
to 20% of patients with a true recurrence (false negatives) and thus multiple modalities are 
recommended [26]. Postoperative CEA is better than preoperative in some studies [9, 10]. There 
exists a clear need for more precise combination of biomarkers. 
CA19-9 is a biomarker widely used in gastrointestinal cancers including CRC; an elevated level has 
been a negative prognostic marker in mCRC [27] and in localized CRC [28-30]. Our patients with 
both post-operatively elevated CEA and CA19-9 relapsed and had short DFS and OS, but CA19-9 
alone was not an independent predictor of relapse and survival in CRC. Some findings are contrary 
to ours [30, 31], but findings in line with ours imply that CA19-9 has potential value in combination 
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with elevated CEA [29, 32, 33]. More convincing data are essential before adoption of CA19-9 
surveillance into clinical practice.  
Chronic inflammation plays an important role in colorectal carcinogenesis and is associated with 
poor prognosis [12], but data concerning YKL-40 as a prognostic post-operative biomarker in CRC 
after radical surgery are limited [34]. YKL-40 has been elevated in CRC patients and more sensitive 
than CEA and CA19-9, especially in localized CRC [35-37]. High levels of pre-treatment YKL-40 
are associated with short OS in chemotherapy for mCRC [38], and in patients undergoing liver 
resection [39]. We demonstrate that in radically resected CRC patients, high YKL-40 is a predictor 
of impaired OS. Furthermore, patients with normal CEA but with elevated YKL-40 had impaired 
DFS (10-year DFS rate estimate 49 vs. 71%) and OS (10-year OS rate 55 vs. 77%). Our findings 
are in line with those of Cintin et al. [34] showing post-operatively elevated YKL-40 to be an 
independent predictor of higher recurrence rates and impaired survival in stage II-IV disease. Our 
patients with concomitantly elevated CEA and YKL-40 had a 90% recurrence rate. As YKL-40 
predicts survival regardless of CEA level, it may add additional information to CEA measurement 
and improve risk stratification. 
Discordant prognostic significance, especially for pre-operative CRP, is evident in one  
comprehensive review [40]. We showed that elevated post-operative CRP associated with impaired 
DFS and OS in univariate analysis, in line with earlier findings [41, 42]. Our patients with normal 
CEA and elevated CRP had significantly worse 10-year DFS rates (30 vs. 65%) and OS rates (40 
vs. 71%) than patients with both markers normal. In fact, all with post-operatively elevated CEA 
and CRP relapsed. Accordingly, CRP is a strong predictor of poor survival, a complementary one to 
CEA. 
Data concerning IL-6 as a prognostic biomarker in CRC are ambiguous according to one review, 
and in most studies presented IL-6 was not an independent prognostic biomarker [43]. Our results 
are in accordance with these findings as IL-6 was prognostic only in univariate analysis for OS, but 
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not in multivariate analysis. In a study with stage I-III CRC patients, those with high pre-operative 
IL-6, had significantly shorter DFS [44], which is in line with our univariate analysis. All our 
patients with concomitantly elevated CEA and IL-6 recurred. 
Post-operatively elevated CEA is prognostic for relapse [9, 10], in line with our findings, and 
identifies patients in need for more intensive adjuvant therapy [45, 46]. Stage II colon cancer 
patients with elevated post-operative CEA benefit from adjuvant therapy vs. surgery alone, or from 
more intensified therapy with addition of oxaliplatin [46, 47].  
Among the strengths of our study are that all patients underwent high-quality surgery followed by 
long-term monitoring. All received adjuvant therapy with 6 months of 5-FU, although without 
oxaliplatin. A further strength is the follow-up routine with clinical examination, routine laboratory 
measurements, including tumour markers, and radiology for 10 years within the prospective study 
at a single institution. Limitations are the small sample sizes in subgroup analyses, resulting in 
limited statistical power. Secondly, as routine CEA, CA19-9, and CRP were not systematically 
analysed pre-operatively, we therefore could not study persistently elevated markers post-
operatively vs. markers that post-operatively normalized. Another limitation is that some sampling 
of biomarkers and initiation of adjuvant therapy was delayed because of delayed referrals, perhaps 
impacting results of efficacy of adjuvant therapy but will probably not have had an influence on the 
prognostic effect of the post-operative markers. These patients were treated in 1997-2001 with 5-
FU-based and the results should be validated in patients treated with oxaliplatin-based 
chemotherapy.  
In conclusion, we showed that post-operatively elevated CEA alone or in combination with postoperatively 
elevated YKL-40, CRP, CA19-9 or IL-6, associate with high recurrence rates in radically resected stage II-IV 
CRC patients. In addition, postoperative normal CEA in combination with elevated YKL-40 or CRP may indicate 
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Table 1 Patient characteristics and postoperative biomarker levels  
 
    All patients Primary location 
      Right colon Left colon Rectum 
 
    n =   147 n= 41 n= 46 n= 60 p 
Sex Male 75 51% 17 41% 24 52% 34 57% .318 
Female 72  49% 24 59% 22 48% 26 43%   
Age Median (range) 60 31-76 60.9 35-74 61.4 31-74 59.2 37-76 .378 
Inflammatory 
disease* 
No 133 91% 37 90% 44 96% 52 87% .295 
Yes 14 9% 4 10% 2 4% 8 13%   
Chemotherapy 
regimen 
5FU+LV bolusinj. 75 51% 20 49% 23 50% 32 53% .891 
5FU+LV cont. 
inf. 
72 49% 21 51% 23 50% 28 47%   
Radiotherapy No 96 65% 41 100% 46 100% 9 15% 
 
Yes 51 35% 0 0% 0 0% 51 85%   
TNM stage IIA-B 38 26% 9 22% 11 24% 18 30% .749 
  IIIA-C 91 62% 25 61% 30 65% 36 60%   
  IV 18 12% 7 17% 5 11% 6 10%   
Relapse site No 82 56% 22 54% 27 59% 33 55% .969 
Local  13 9% 4 10% 3 7% 6 10%   
Distal 52 35% 15 37% 16 35% 21 35%   
CEA1, ug/l Median (range) 1.9 <1-305 1.7 <1-89 2.0 <1-102 1.9 <1-305 .239 
CA19-92 kU/l Median (range) 6 <5-2003 5 <5-2003 <5 <5-67 7 <5-934 .150 
YKL-403ng/ml Median (range) 65 20-1524 65 20-242 55 20-1524 77 20-504 .451 
CRP4, mg/l Median (range) <5 1-174 <5 4-174 <5 1-23 <5 1-35 .155 
IL-65, pg/ml  Median (range) 2.3 .38-36 2.0 .38-36 2.2 .62-13.8 2.8 .46-20.1 .019 
*Inflammatory diseases adjusted for: autoimmune diseases as rheumatoid arthritis, iritis, psoriasis, ulcerative colitis, 
coeliac disease and thyroiditis  
5FU+LV = 5-fluorouracil and leucovorin with randomization to bolus injection (Mayo regimen) or continuous infused 
(de Gramont regimen). 





Table 2. Number of patients with no relapse, vs. relapse with or without CRC death and other 
competing non-CRC deaths, assessed at 7 years. Sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) for all 147 patients and subgroups, 101 with 
normal and 18 with elevated CEA. 
 







NPV and PPV Sensitivity and 
Specificity 
All CEA ≤5 114 73 35 6 NPV 64 % Specificity 97 % 
 >5 18 2 16 0 PPV 89 % Sensitivity 31 % 
 CA19-9 ≤26 113 62 46 5 NPV 55 % Specificity 89 % 
 >26 17 8 9 0 PPV 53 % Sensitivity 16 % 
 YKL-
40 
≤701  81 51 28 2 NPV 63 % Specificity 69 % 
 >70.7 63 23 36 4 PPV 57 % Sensitivity 56 % 
 CRP ≤10 129 72 52 5 NPV 56 % Specificity 96 % 
 >10 17 3 13 1 PPV 77 % Sensitivity 20 % 
 IL-6 ≤4.5 119 66 47 6 NPV 56 % Specificity 92 % 
  >4.5 24 6 18 0 PPV 75 % Sensitivity  28 % 
CEA ≤5 
CA19-9 ≤26 95 60 30 5 NPV 63 % Specificity 88 % 
>26 11 8 3 0 PPV 27 % Sensitivity 9 % 
YKL-
40 
≤70.7 68 50 16 2 NPV 73 % Specificity 69 % 
>70.7 45 22 19 4 PPV 42 % Sensitivity 54 % 
CRP ≤10 103 69 29 5 NPV 67 % Specificity 96 % 
>10 10 3 6 1 PPV 60 % Sensitivity 17 % 
IL-6 ≤4.5 98 64 28 6 NPV 65 % Specificity 91 % 
>4.5 13 6 7 0 PPV 54 % Sensitivity 20 % 
CEA >5 
CA19-9 ≤26 8 1 7 0 NPV 13 % Specificity 100 % 
>26 5 0 5 0 PPV 100 % Sensitivity 88 % 
YKL-
40 
≤70.7 8 1 7 0 NPV 13 % Specificity 50 % 
>70.7 10 1 9 0 PPV 90 % Sensitivity 56 % 
CRP ≤10 14 2 12 0 NPV 14 % Specificity 100 % 
>10 4 0 4 0 PPV 100 % Sensitivity 25 % 
IL-6 ≤4.5 12 2 10 0 NPV 17 % Specificity 100 % 
>4.5 6 0 6 0 PPV 100 % Sensitivity 38 % 
NPV = negative predictive value, PPV= positive predictive value  
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Unadjusted CI95% for HR  P-value CI95% for HR  P-value 
Age ≤60 (n=72) vs. >60  .77 .47 1.25 .284 1.96 1.20 3.19 .007 
Sex: Female (n=72) vs. Male .81 .50 1.32 .404 .86 .54 1.39 .541 
Tumour location         
   Right (n=41) 1      1      
   Left (n=46) .88 .47 1.67 .703 .87 .46 1.63 .661 
   Rectal (n=60) .95 .53 1.71 .869 1.03 .58 1.82 .931 
Inflammatory disease (n=14) 1.53 .73 3.20 .263 1.10 .50 2.40 .815 
Tumour stage         
   Stage II (n=38)  1      1      
   Stage III (n=91) 2.41 1.17 4.94 .017 1.45 .78 2.70 .245 
   Stage IV (n=18) 5.82 2.48 13.65 <..001 3.91 1.83 8.37 <.001 
Chemo: LV5FU2 (n=72) .76 .47 1.24 .274 .73 .45 1.18 .201 
Adjusted*         
CEA1 elevated vs. normal 7.23 3.85 13.58 <.001 7.16 3.76 13.63 <.001 
CA19-92 elevated vs. normal 1.98 .99 3.97 .054 1.94 .93 4.04 .076 
YKL-403 elevated vs. normal 1.84 1.14 2.96 .013 1.97 1.20 3.23 .007 
CRP4 elevated vs. normal 2.31 1.21 4.39 .011 2.40 1.20 4.80 .013 
IL-65 elevated vs. normal 1.77 .95 3.30 .071 1.99 1.05 3.76 .035 
Multivariate model** 
(n=104)               
Age ≤60 vs. >60 years 1.36 .76 2.45 .300 1.82 .96 3.43 .065 
Sex: Female vs. Male .83 .47 1.48 .534 .76 .41 1.41 .389 
Inflammatory disease .54 .18 1.62 .272 .23 .06 .85 .028 
Tumour stage         
   TNM stage II 1       1       
   TNM stage III 1.72 .80 3.69 .167 1.54 .68 3.47 .301 
   TNM stage IV 2.65 1.03 6.84 .043 2.47 .87 6.97 .088 
CEA1 elevated vs. normal 8.63 3.82 19.50 <.001 1.17 4.35 23.79 <.001 
CA19-92 elevated vs. normal 1.16 .51 2.64 .731 1.06 .45 2.51 .897 
YKL-403 elevated vs. normal 1.58 .88 2.86 .126 2.24 1.23 4.05 .008 
CRP4 elevated vs. normal 2.53 1.10 5.81 .028 2.49 .95 6.51 .063 
IL-64 elevated vs. normal 1.17 .50 2.73 .713 1.14 .48 2.71 .772 
* adjusted for age, sex, inflammatory disease and stage. 
** Variables included CEA, CA 19-9, YKL-40, CRP and IL-6; age, sex, inflammatory disease, stage.  






Figure 1. Disease-free survival (DFS, panel A) and overall survival (OS) (panel B) in post-
operatively elevated vs. normal CEA.  
 
 
Figure 2.    The subgroup with normal post-operative CEA and elevated YKL-40 with disease free 
survival (DFS) in panel A and overall survival (OS) in panel B and the subgroup with normal 
postoperative CEA and elevated CRP with DFS in panel C and OS in panel D. 
 
 
 
